Biodesix, Inc. (BDSX) vs MacroGenics, Inc. (MGNX)
A side-by-side comparison of Biodesix, Inc. and MacroGenics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BDSX
Biodesix, Inc.
$28.49HealthcareDelayed quote: Oct 6, 2026, 12:05 PM EDT
MGNX
MacroGenics, Inc.
$3.72HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — BDSX vs MGNX
growth of $100 · dividends reinvested · last 6yBDSX -88.7% (-30.4%/yr)MGNX -82.9% (-25.5%/yr)MGNX compounded faster over this window
BDSX MGNX
BDSX vs MGNX: by the numbers
- •MGNX is the larger company ($236M vs $232M market cap).
- •Both run net losses; MGNX's is the smaller (-8.70% vs -26.97% net margin).
- •MGNX grew revenue faster over the past five years (7.33% vs 5.99% CAGR).
Metrics side by side
Valuation
| Metric | BDSX | MGNX |
|---|---|---|
| P/S ratio | 2.25 | 1.41 |
| P/B ratio | 25.36 | 5.51 |
Profitability
| Metric | BDSX | MGNX |
|---|---|---|
| Gross margin | 82.50% | 71.12% |
| Operating margin | -31.37% | -48.72% |
| Net margin | -26.97% | -8.70% |
| ROE | -303.61% | -34.04% |
| ROIC | -25.73% | -16.87% |
Growth (annualized)
| Metric | BDSX | MGNX |
|---|---|---|
| Revenue CAGR (5Y) | 5.99% | 7.33% |
| Total return CAGR (5Y) | -28.49% | -28.42% |
Frequently asked
- Which has grown faster, BDSX or MGNX?
- Over the past five years, MGNX grew revenue faster — BDSX at a 5.99% CAGR versus MGNX at 7.33%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.